Andrew Deavin | Senior Director
GSK

After obtaining a M.Sc. and Ph.D in Immunology and a period working in vaccine research, Andrew Deavin has spent the past 30 years in Regulatory Affairs covering UK, Europe and International. He has managed regulatory projects in development, registration and life-cycle primarily in vaccines but also in haematology/oncology focussing on strategy and issue resolution. He is currently in Regulatory Policy working externally to reduce complexity in the regulatory environment and enhance access to innovative vaccine products. This includes active engagement in various industry associations as well as presenting externally on different regulatory topics. Amongst several activities, Andrew is the Chair of the Vaccines Europe Regulatory Affairs Working Group, a vaccine task force lead for the International Federation of Pharmaceutical Manufacturers and Associations, and is part of the European Medicines Agency's Focus Group on Regulatory Reliance. Andrew is GSK's Policy Lead supporting Vaccines as well as Regulatory Policy Lead for GSK products in Greater China and Intercontinental region (which includes China, Japan, Korea and Canada). Andrew is currently based in Belgium.